Key Insights

Highlights

Success Rate

100% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 32 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

3%

1 trials in Phase 3/4

Results Transparency

0%

0 of 5 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

24Total
Not Applicable (8)
P 1 (1)
P 2 (14)
P 3 (1)

Trial Status

Recruiting14
Not Yet Recruiting8
Completed5
Active Not Recruiting3
Unknown1
Withdrawn1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 5 completed trials

Clinical Trials (32)

Showing 20 of 20 trials
NCT06824688Not ApplicableRecruitingPrimary

Single-port Versus Multi-port Robotic Surgery for Rectal Cancer

NCT07722533Not ApplicableCompletedPrimary

Role of Serial C-reactive Protein Concentration Analysis With Computed Tomography in Limiting the Need for Protective Defunctioning Ileostomy After Laparoscopic Low Anterior Resection - A Prospective Study

NCT07687875Phase 1RecruitingPrimary

Oncolytic Virotherapy to Enhance PReoperative IMmunotherapy Efficacy in Patients With Proficient Mismatch Repair (pMMR) Rectal Cancer

NCT07695519Not Yet Recruiting

SCARLET - Italian proSpeCtionAl obseRvationaL multicEntre Study on Treatment for recTal pT1 Cancer

NCT07687433Phase 2Active Not RecruitingPrimary

Long-Course Concurrent Chemoradiotherapy With Adebrelimab and Apatinib as Neoadjuvant Therapy for Locally Advanced/Low-Lying Rectal Cancer Requiring Sphincter Preservation

NCT03051464Phase 2Recruiting

Randomizing Two Radiotherapy Boost Options to Avoid Rectal Cancer Surgery

NCT07663071Phase 2Active Not RecruitingPrimary

Short-course Radiotherapy Combined With Retlirafusp Alfa and CAPOX Chemotherapy as Neoadjuvant Therapy for Locally Advanced Rectal Cancer: A Prospective, Single-arm, Phase II Clinical Study

NCT07651553Not ApplicableRecruitingPrimary

Transanal Total Mesorectal Excision vs Robotic Total Mesorectal Excision

NCT07176182Phase 2RecruitingPrimary

Clinical Trial of Neoadjuvant mFOLFOX Plus Alvenor for LARC Patients With High YWHAB Expression

NCT07389863RecruitingPrimary

Evaluation of Gynecological and Sexual Sequelae

NCT07557316Not Yet RecruitingPrimary

Nodal Downstaging Versus Primary Tumor Regression as Predictors of Survival After Total Neoadjuvant Therapy for Rectal Cancer: A Retrospective Study

NCT06911684Phase 2RecruitingPrimary

Radiotherapy Plus Iparomlimab and Tuvonralimab (QL1706), Regorafenib, and CAPOX as Neoadjuvant Therapy for pMMR/MSS LARC.

NCT06850090Phase 3Recruiting

Neoadjuvant Radiotherapy for Rectal Adenocarcinoma With Capecitabine Versus TAS-102 (Neo-REACT): A Multi-center, Randomized, Phase III Trial

NCT07522294Not ApplicableActive Not Recruiting

Optimization and Standardization of Single-Port Robotic Transanal Minimally Invasive Surgery for Rectal Tumor Excision

NCT07521605Phase 2Not Yet RecruitingPrimary

Short-Course Radiotherapy, Nal-IRI, Capecitabine, and Camrelizumab for Locally Advanced MSS Rectal Cancer

NCT06647680Phase 2RecruitingPrimary

Neoadjuvant Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer(CONTROL-01)

NCT07358247Not Yet RecruitingPrimary

Postoperative Outcomes of Single-stapled Anastomosis Combined With Transanal Natural Orifice Specimen Extraction

NCT07337811Not ApplicableRecruitingPrimary

Selective Total Mesorectal Excision Based on Intra-Operative Frozen Section From Local Excision in Rectal Cancer Undergoing Neoadjuvant Chemoradiotherapy

NCT07314528Phase 2Not Yet RecruitingPrimary

Evaluating the Impact of GLP-1 Receptor Agonists With Total Neoadjuvant Therapy in Rectal Cancer

NCT07291401Phase 2Not Yet RecruitingPrimary

Radiotherapy Plus CAPOX, and Iparomlimab and Tuvonralimab (QL1706) as Neoadjuvant Therapy for LARC

Scroll to load more

Research Network

Activity Timeline